Compare FINV & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FINV | COLL |
|---|---|---|
| Founded | 2007 | 2002 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2017 | 2015 |
| Metric | FINV | COLL |
|---|---|---|
| Price | $4.94 | $35.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $12.10 | ★ $51.40 |
| AVG Volume (30 Days) | ★ 713.9K | 424.2K |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.09% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.40 |
| Revenue | N/A | ★ $780,567,000.00 |
| Revenue This Year | N/A | $8.01 |
| Revenue Next Year | $10.58 | N/A |
| P/E Ratio | ★ $3.87 | $90.50 |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $4.35 | $29.19 |
| 52 Week High | $10.90 | $50.79 |
| Indicator | FINV | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 52.09 | 60.06 |
| Support Level | $4.67 | $33.80 |
| Resistance Level | $5.23 | $48.74 |
| Average True Range (ATR) | 0.17 | 1.36 |
| MACD | 0.00 | 0.29 |
| Stochastic Oscillator | 65.45 | 83.81 |
FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.